Validation of two diagnostic blood-marker tests for ALS and Alzheimer’s disease.

Dr. Rachael Dunlop runs our qPCR for microRNA disease diagnostics.

Our discoveries of blood diagnostic tests for ALS (based on microRNA) and Alzheimer’s disease (based on a unique metabolite) have now been published in prestigious scientific journals.

We are busily engaged in the painstaking process of validating these tests, using samples from the Centers for Disease Control for ALS, and previous samples from our Phase II early-stage Alzheimer’s trial.

We seek a pharmaceutical partner to commercialize these blood diagnostics so they can be made available to the public.

Our mission is to rapidly improve patient outcomes for serious brain diseases and thus, we want these diagnostic tests in the hands of neurologists as soon as possible.

New Alzheimer’s Biomarker May Facilitate Rapid Diagnosis

Discovery of a unique ratio of metabolites from blood samples of early-stage Alzheimer’s patients promises to speed diagnosis of Alzheimer’s disease.

Although symptoms of advanced Alzheimer’s disease are well known, diagnosis of Alzheimer’s disease in its earliest stages requires careful cognitive testing by neurologists.

Discovery of a unique ratio of metabolites from blood samples of early-stage Alzheimer’s patients promises to speed diagnosis, allowing earlier treatments to be initiated.

“We were delighted to discover that the ratio of two molecules, 2-aminoethyl dihydrogen phosphate and taurine, allows us to reliably discriminate samples of early-stage Alzheimer’s patients from controls,” said Dr. Sandra Banack, lead author of the report in PLOS ONE and Senior Scientist at the Brain Chemistry Labs in Jackson Hole.

Dr. Sandra Banack works on the amino acid analyzer in the Brain Chemistry Labs, Jackson, Wyoming.

The blood samples were drawn from patients enrolled in an FDA-approved Phase II trial at Dartmouth Hitchcock Medical Center in New Hampshire and then shipped to the Brain Chemistry Labs for analysis. Current attempts to diagnose Alzheimer’s disease from blood samples depend on the presence of amyloid fragments, the molecules that cause brain tangles and plaques.

“At the Brain Chemistry Labs, we consider amyloid plaques to be a consequence rather than the cause of Alzheimer’s disease,” Dr. Paul Alan Cox, Executive Director of the Brain Chemistry Labs explains. “What is exciting about this new discovery is that it does not depend on amyloid and the assay can be performed on analytical equipment that is already present in most large hospitals.”

Their report, written with Alzheimer’s expert Dr. Aleksandra Stark, “A Possible Blood Plasma Biomarker for Early-stage Alzheimer’s Disease” is being published this week in PLOS ONE.

---

About the Brain Chemistry Labs: The Brain Chemistry Labs is a not-for-profit research institute based in Jackson Hole focused on improving outcomes for patients suffering from Alzheimer’s, ALS, and other neurodegenerative illnesses.

Contacts:
Dr. Sandra Banack, Tel: 307-734-1680, sandra@ethnomedicine.org
Dr. Paul Alan Cox, Tel: 801-375-6214, paul@ethnomedicine.org

Download our press release here